Epigenetics and autosomal dominant polycystic kidney disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 10, 2011, Pages 1213-1218

  Li, Xiaogang ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Tubulin; Autosomal dominant polycystic kidney disease; Epidermal growth factor receptor; Epigenetic; HDAC inhibitor; Histone deacetylases

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 PHENYLBUTYRIC ACID; ALPHA TUBULIN; BELINOSTAT; BETA CATENIN; BUTYRIC ACID; EPIDERMAL GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; MYOCYTE ENHANCER FACTOR 2; PANOBINOSTAT; POLYCYSTIN 1; PROTEIN KINASE C; PROTEIN P53; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACETYLATION; AMINO TERMINAL SEQUENCE; AXONEME; BINDING AFFINITY; BINDING SITE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CENTRIOLE; CENTROSOME; CUTANEOUS T CELL LYMPHOMA; CYTOPLASM; DEACETYLATION; DISEASE COURSE; DOWN REGULATION; ENDOCYTOSIS; EPIGENETICS; EPITHELIUM CELL; FEEDBACK SYSTEM; FLUID FLOW; GENE EXPRESSION; HEART HYPERTROPHY; HISTONE PHOSPHORYLATION; HUMAN; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LOSS OF FUNCTION MUTATION; LUNG CANCER; MECHANICAL STRESS; MICROARRAY ANALYSIS; MICROTUBULE; MITOSIS; MUSCLE DEVELOPMENT; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MODELS, BIOLOGICAL; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS;

MUS;

EID: 80052271347     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.10.008     Document Type: Review

References (80)

1. Gabow P.A. Autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 1993, 22:511-512.
2. Peters D.J., Sandkuijl L.A. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib. Nephrol. 1992, 97:128-139.
3. Chen X.Z., Vassilev P.M., Basora N., Peng J.B., Nomura H., Segal Y., Brown E.M., Reeders S.T., Hediger M.A., Zhou J. Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature 1999, 401:383-386.
4. Gonzalez-Perrett S., Kim K., Ibarra C., Damiano A.E., Zotta E., Batelli M., Harris P.C., Reisin I.L., Arnaout M.A., Cantiello H.F. Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc. Natl Acad. Sci. USA 2001, 98:1182-1187.
5. Hanaoka K., Qian F., Boletta A., Bhunia A.K., Piontek K., Tsiokas L., Sukhatme V.P., Guggino W.B., Germino G.G. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 2000, 408:990-994.
6. Koulen P., Cai Y., Geng L., Maeda Y., Nishimura S., Witzgall R., Ehrlich B.E., Somlo S. Polycystin-2 is an intracellular calcium release channel. Nat. Cell Biol. 2002, 4:191-197.
7. Thivierge C., Kurbegovic A., Couillard M., Guillaume R., Cote O., Trudel M. Overexpression of PKD1 causes polycystic kidney disease. Mol. Cell. Biol. 2006, 26:1538-1548.
8. Chang M.Y., Parker E., Ibrahim S., Shortland J.R., Nahas M.E., Haylor J.L., Ong A.C. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol. Dial. Transplant. 2006, 21:2078-2084.
9. Jones R.S. Epigenetics: reversing the 'irreversible'. Nature 2007, 450:357-359.
10. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
11. Luger K. Structure and dynamic behavior of nucleosomes. Curr. Opin. Genet. Dev. 2003, 13:127-135.
12. Gregory P.D., Wagner K., Horz W. Histone acetylation and chromatin remodeling. Exp. Cell Res. 2001, 265:195-202.
13. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
14. Lee D.Y., Hayes J.J., Pruss D., Wolffe A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993, 72:73-84.
15. Gray S.G., Teh B.T. Histone acetylation/deacetylation and cancer: an "open" and "shut" case?. Curr. Mol. Med. 2001, 1:401-429.
16. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet. 2007, 8:829-833.
17. Oki M., Aihara H., Ito T. Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Subcell. Biochem. 2007, 41:319-336.
18. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 2003, 983:84-100.
19. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
20. Mariadason J.M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008, 3:28-37.
21. Taplick J., Kurtev V., Kroboth K., Posch M., Lechner T., Seiser C. Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J. Mol. Biol. 2001, 308:27-38.
22. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272:408-411.
23. Bertos N.R., Wang A.H., Yang X.J. Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 2001, 79:243-252.
24. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277:25748-25755.
25. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404:1-13.
26. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73:417-435.
27. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
28. Gray S.G., Ekstrom T.J. The human histone deacetylase family. Exp. Cell Res. 2001, 262:75-83.
29. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
30. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
31. Marzio G., Wagener C., Gutierrez M.I., Cartwright P., Helin K., Giacca M. E2F family members are differentially regulated by reversible acetylation. J. Biol. Chem. 2000, 275:10887-10892.
32. Patel J.H., Du Y., Ard P.G., Phillips C., Carella B., Chen C.J., Rakowski C., Chatterjee C., Lieberman P.M., Lane W.S., Blobel G.A., McMahon S.B. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol. Cell. Biol. 2004, 24:10826-10834.
33. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
34. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111:709-720.
35. Ammanamanchi S., Freeman J.W., Brattain M.G. Acetylated sp3 is a transcriptional activator. J. Biol. Chem. 2003, 278:35775-35780.
36. Braun H., Koop R., Ertmer A., Nacht S., Suske G. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 2001, 29:4994-5000.
37. Imhof A., Yang X.J., Ogryzko V.V., Nakatani Y., Wolffe A.P., Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 1997, 7:689-692.
38. Boyes J., Byfield P., Nakatani Y., Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998, 396:594-598.
39. Waltzer L., Bienz M. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 1998, 395:521-525.
40. Munshi N., Merika M., Yie J., Senger K., Chen G., Thanos D. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol. Cell 1998, 2:457-467.
41. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21:6236-6245.
42. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., Adcock I.M. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 2006, 203:7-13.
43. Gregoire S., Xiao L., Nie J., Zhang X., Xu M., Li J., Wong J., Seto E., Yang X.J. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol. Cell. Biol. 2007, 27:1280-1295.
44. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
45. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18:601-607.
46. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., Milutinovic N., Kratchmarova I., Buerkle L., Fetchko M.J., Schmidt P., Kittanakom S., Brown K.R., Jurisica I., Blagoev B., Zerial M., Stagljar I., Dikic I. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal. 2009, 2:ra84.
47. Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008, 18:291-297.
48. Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007, 129:1351-1363.
49. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280:26729-26734.
50. Van Bodegom D., Saifudeen Z., Dipp S., Puri S., Magenheimer B.S., Calvet J.P., El-Dahr S.S. The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression. J. Biol. Chem. 2006, 281:31234-31244.
51. Enya K., Hayashi H., Takii T., Ohoka N., Kanata S., Okamoto T., Onozaki K. The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL-1 alpha in human melanoma cells. J. Leukoc. Biol. 2008, 83:190-199.
52. Xia S., Li X., Johnson T., Seidel C., Wallace D.P., Li R. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 2010, 137:1075-1084.
53. McKinsey T.A., Zhang C.L., Olson E.N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 2002, 27:40-47.
54. Haberland M., Arnold M.A., McAnally J., Phan D., Kim Y., Olson E.N. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol. Cell. Biol. 2007, 27:518-525.
55. Wang D.Z., Valdez M.R., McAnally J., Richardson J., Olson E.N. The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development. Development 2001, 128:4623-4633.
56. Wang W., Ha C.H., Jhun B.S., Wong C., Jain M.K., Jin Z.G. Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS. Blood 2009.
57. Vong L.H., Ragusa M.J., Schwarz J.J. Generation of conditional Mef2cloxP/loxP mice for temporal- and tissue-specific analyses. Genesis 2005, 43:43-48.
58. Rubera I., Poujeol C., Bertin G., Hasseine L., Counillon L., Poujeol P., Tauc M. Specific Cre/Lox recombination in the mouse proximal tubule. J. Am. Soc. Nephrol. 2004, 15:2050-2056.
59. Wu G., D'Agati V., Cai Y., Markowitz G., Park J.H., Reynolds D.M., Maeda Y., Le T.C., Hou H., Kucherlapati R., Edelmann W., Somlo S. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 1998, 93:177-188.
60. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., Lazar M.A., Voelter W., Verdin E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 2002, 9:45-57.
61. Cao Y., Semanchik N., Lee S.H., Somlo S., Barbano P.E., Coifman R., Sun Z. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc. Natl Acad. Sci. USA 2009, 106:21819-21824.
62. Praetorius H.A., Spring K.R. A physiological view of the primary cilium. Annu. Rev. Physiol. 2005, 67:515-529.
63. Pan J., Snell W. The primary cilium: keeper of the key to cell division. Cell 2007, 129:1255-1257.
64. Veland I.R., Awan A., Pedersen L.B., Yoder B.K., Christensen S.T. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol. 2009, 111:39-53.
65. Cadigan K.M., Peifer M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harb. Perspect. Biol. 2009, 1:a002881.
66. Kim E., Arnould T., Sellin L.K., Benzing T., Fan M.J., Gruning W., Sokol S.Y., Drummond I., Walz G. The polycystic kidney disease 1 gene product modulates Wnt signaling. J. Biol. Chem. 1999, 274:4947-4953.
67. Song X., Di Giovanni V., He N., Wang K., Ingram A., Rosenblum N.D., Pei Y. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum. Mol. Genet. 2009, 18:2328-2343.
68. Lu Z., Ghosh S., Wang Z., Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4:499-515.
69. Li Y., Zhang X., Polakiewicz R.D., Yao T.P., Comb M.J. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J. Biol. Chem. 2008, 283:12686-12690.
70. Amit S., Hatzubai A., Birman Y., Andersen J.S., Ben-Shushan E., Mann M., Ben-Neriah Y., Alkalay I. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 2002, 16:1066-1076.
71. Sweeney W.E., Avner E.D. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease. Cell Tissue Res. 2006, 326:671-685.
72. Du J., Wilson P.D. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am. J. Physiol. 1995, 269:C487-C495.
73. Gattone V.H., Kuenstler K.A., Lindemann G.W., Lu X., Cowley B.D., Rankin C.A., Calvet J.P. Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse. J. Lab. Clin. Med. 1996, 127:214-222.
74. Nauta J., Sweeney W.E., Rutledge J.C., Avner E.D. Biliary epithelial cells from mice with congenital polycystic kidney disease are hyperresponsive to epidermal growth factor. Pediatr. Res. 1995, 37:755-763.
75. Orellana S.A., Sweeney W.E., Neff C.D., Avner E.D. Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney Int. 1995, 47:490-499.
76. Richards W.G., Sweeney W.E., Yoder B.K., Wilkinson J.E., Woychik R.P., Avner E.D. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J. Clin. Invest. 1998, 101:935-939.
77. Sweeney W.E., Avner E.D. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease. Am. J. Physiol. 1998, 275:F387-F394.
78. Kamemura K., Ito A., Shimazu T., Matsuyama A., Maeda S., Yao T.P., Horinouchi S., Khochbin S., Yoshida M. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. Biochem. Biophys. Res. Commun. 2008, 374:84-89.
79. Mai A., Valente S., Nebbioso A., Simeoni S., Ragno R., Massa S., Brosch G., De Bellis F., Manzo F., Altucci L. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. Int. J. Biochem. Cell Biol. 2009, 41:235-247.
80. Sweeney W.E., von Vigier R.O., Frost P., Avner E.D. Src inhibition ameliorates polycystic kidney disease. J. Am. Soc. Nephrol. 2008, 19:1331-1341.